Loading...
AGTC logo

Applied Genetic Technologies CorporationNasdaqGM:AGTC Stok Raporu

Piyasa Değeri US$12.6m
Hisse Fiyatı
n/a
Adil Değerim
Kullanılamıyor
1Y-80.9%
7D4.8%
1D
Portföy Değeri
​
Görünüm

Applied Genetic Technologies Corporation

NasdaqGM:AGTC Stok Raporu

Piyasa değeri: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies (AGTC) Hisse Özeti

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Daha fazla detay

Ödüller

Gelirin yılda 68.05% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $325K )

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Anlamlı bir piyasa değeri yok ( $13M )

+ 1 daha fazla risk

AGTC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Applied Genetic Technologies Corporation Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Applied Genetic Technologies
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$0.39
52 Haftanın En Yüksek SeviyesiUS$2.83
52 Haftanın En Düşük SeviyesiUS$0.23
Beta1.58
1 Aylık Değişim-4.23%
3 Aylık Değişim-1.85%
1 Yıllık Değişim-80.89%
3 Yıllık Değişim-86.79%
5 Yıllık Değişim-89.78%
Halka arzdan bu yana değişim-97.33%

Son Haberler & Güncellemeler

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering

Recent updates

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Seeking Alpha • Jan 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14

An Assessment Of Applied Genetic Technologies Corporation

In the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Jul 15

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
Analiz Makalesi • May 21

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi • Feb 05

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
Analiz Makalesi • Jan 06

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi • Dec 11

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Hissedar Getirileri

AGTCUS BiotechsUS Pazar
7D4.8%2.4%1.1%
1Y-80.9%34.6%28.7%

Getiri vs. Endüstri: AGTC geçen yıl % 34.6 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: AGTC geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AGTC's price volatile compared to industry and market?
AGTC volatility
AGTC Average Weekly Movement19.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: AGTC hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: AGTC 'nin haftalık oynaklığı ( 20% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1999102Sue Washeragtc.com

Applied Genetic Technologies Corporation Temel Bilgiler Özeti

Applied Genetic Technologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AGTC temel i̇stati̇sti̇kler
Piyasa değeriUS$12.62m
Kazançlar(TTM)-US$70.23m
Gelir(TTM)US$325.00k
38.9x
P/S Oranı
-0.2x
F/K Oranı

AGTC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AGTC gelir tablosu (TTM)
GelirUS$325.00k
Gelir MaliyetiUS$21.76m
Brüt Kâr-US$21.44m
Diğer GiderlerUS$48.80m
Kazançlar-US$70.23m

Son Raporlanan Kazançlar

Sep 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.19
Brüt Marj-6,596.62%
Net Kâr Marjı-21,610.46%
Borç/Özkaynak Oranı92.6%

AGTC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2022/12/01 19:58
Gün Sonu Hisse Fiyatı2022/11/30 00:00
Kazançlar2022/09/30
Yıllık Kazançlar2022/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Applied Genetic Technologies Corporation 10 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
James BirchenoughBMO Capital Markets Equity Research
Yun ZhongBrean Capital Historical (Janney Montgomery)
Yun ZhongBTIG